0

<< Emergency Management Of Coagulopathy In Acute Intracranial Hemorrhage (Stroke CME)

References

TOC Will Appear Here

References

References

Evidence-based medicine requires a critical appraisal of the literature based upon study methodology and number of subjects. Not all references are equally robust. The findings of a large, prospective, randomized, and blinded trial should carry more weight than a case report.

To help the reader judge the strength of each reference, pertinent information about the study, such as the type of study and the number of patients in the study, will be included in bold type following the reference, where available. In addition, the most informative references cited in this paper, as determined by the authors, will be noted by an asterisk (*) next to the number of the reference.

  1. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke. 2006;37(1):256-262. (Review)
  2. Flibotte JJ, Hagan N, O’Donnell J, et al. Hematoma expansion and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059-1064. (Prospective observational; 183 patients)
  3. Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6):257S-298S. (Evidence-based clinical practice guidelines)
  4. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348(9025):423-428. (Prospective observational study; 2745 patients)
  5. Abdelhafiz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Ther. 2004;26(9):1470-1478. (Prospective observational study; 402 patients)
  6. Jackson SL, Peterson GM, Vial JH, et al. Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Intern Med J. 2001;31(6):329-336. (Retrospective study; 505 patients)
  7. * Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3):287S-310S. (Review, practice guidelines)
  8. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307(27):1676-1681.(Prospective randomized trial; 96 patients)
  9. Saour JN, Sieck JO, Mamo LA, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med. 1990;322(7):428-432. (Prospective randomized trial; 258 patients)
  10. Franke CL, de Jonge J, van Swieten JC, et al. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990;21(5):726-730. (Retrospective case control study; 163 patients)
  11. Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164(8):880-884. (Prospective observational; 435 patients)
  12. Yasaka M, Minematsu K, Naritomi H, et al. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost. 2003;89(2):278-283. (Retrospective; 47 patients)
  13. Cohen DB, Rinker C, Wilberger JE. Traumatic brain injury in anticoagulated patients. J Trauma. 2006;60(3):553-557. (Retrospective; 159 patients)
  14. Ferrera PC, Bartfield JM. Outcomes of anticoagulated trauma patients. Am J Emerg Med. 1999;17(2):154-156. (Retrospective; 35 patients)
  15. Franko J, Kish KJ, O’Connell BG, et al. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma. 2006;61(1):107-110. (Retrospective; 1493 patients)
  16. Mattle H, Kohler S, Huber P, et al. Anticoagulation-related intracranial extracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 1989;52(7):829-837. (Retrospective case control; 116 patients)
  17. Mina AA, Knipfer JF, Park DY, et al. Intracranial complications of preinjury anticoagulation in trauma patients with head injury. J Trauma. 2002;53(4):668-672. (Retrospective; 380 patients)
  18. Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68(2):116-121. (Retrospective; 762 patients)
  19. Ivascu FA, Howells GA, Junn FS, et al. Rapid warfarin reversal in anticoagulated patients with traumatic intracranial hemorrhage reduces hemorrhage progression and mortality. J Trauma. 2005;59(5):1131-1139. (Prospective observational; 82 patients)
  20. Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297(18):2018-2024. (Systematic review)
  21. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066-2078. (Prospective randomized controlled trial; 7554 patients)
  22. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502. (Prospective randomized controlled trial; 12,562 patients)
  23. Serebruany VL, Malinin AI, Ferguson JJ, et al. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol. 2008;22(3):315-321. (Meta-analysis)
  24. van der Heijden JF, Hutten BA, Buller HR, et al. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2002(1):CD002001. (Meta-analysis)
  25. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost. 2003;1(9):1906-1913. (Meta-analysis)
  26. * Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. Jun 2008;133(6):160S-198S. (Review, practice guidelines)
  27. Cattaneo M. Antiplatelet agents. Hematol J. 2004;5 Suppl 3:S170-174. (Review)
  28. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978;61(2):314-319. (In vitro laboratory study)
  29. Bradlow BA, Chetty N. Dosage frequency for suppression of platelet function by low dose aspirin therapy. Thromb Res. 1982;27(1):99-110. (In vitro laboratory study)
  30. Gerstein NS, Schulman PM, Gerstein WH, et al. Should more patients continue aspirin therapy perioperatively? Clinical Impact of the Aspirin Withdrawal Syndrome. Ann of Surgery. Accepted for publication; in press. (Review)
  31. Weber AA, Braun M, Hohlfeld T, et al. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol. 2001;52(3):333-336. (Prospective observational; 10 subjects)
  32. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. (Prospective randomized controlled trial; 13,608 patients)
  33. Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost. 2010;103(6):1128-1135. (Review)
  34. Angiolillo DJ. Applying platelet function testing in clinical practice: what are the unmet needs? JAMA. 2011;306(11):1260-1261. (Editorial)
  35. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1):64S-94S.(Review)
  36. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154(1):49-56. (Prospective randomized controlled trial; 131 patients)
  37. Bauer KA. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. Chest. 2003;124(6):364S-370S. (Review)
  38. Appelboam R, Thomas EO. The headache over warfarin in British neurosurgical intensive care units: a national survey of current practice. Intensive Care Med. 2007;33(11):1946-1953. (Survey study; 32 subjects)
  39. Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood. 2011;117(23):6091-6099. (Review)
  40. Nee R, Doppenschmidt D, Donovan DJ, et al. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol. 1999;83(2):286-288, A286-287. (Randomized controlled trial; 57 patients)
  41. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007;82(1):82-92. (Review)
  42. Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med. 1999;159(22):2721-2724. (Randomized controlled trial; 22 patients)
  43. Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163(20):2469-2473. (Prospective randomized controlled trial; 66 reversal episodes)
  44. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost. 2006;4(9):1853-1863. (Systematic review)
  45. Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol. 2002;89(4):400-406. (Retrospective)
  46. Wallis JP, Lubenko A, Wells AW, et al. Single hospital experience of TRALI. Transfusion. 2003;43(8):1053-1059. (Retrospective; 11 patients)
  47. Toy P, Gajic O, Bacchetti P, et al. Transfusion related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757-1767.
  48. Eder AF, Herron RM, Jr., Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion. 2010;50(8):1732-1742. (Retrospective; 77 patients)
  49. Arinsburg SA, Skerrett DL, Karp JK, et al. Conversion to low transfusion-related acute lung injury (TRALI)-risk plasma significantly reduces TRALI. Transfusion. Nov 7 2011. [Epub ahead of print] (Retrospective; 2156 patients)
  50. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;77(3):477-480. (Prospective observational; 12 patients)
  51. Goldstein JN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006;37(1):151-155. (Prospective observational; 69 patients)
  52. Menzin J, Hoesche J, Friedman M, et al. Failure to correct international normalized ratio and mortality among patients with warfarin-related major bleeding: an analysis of electronic health records. J Thromb Haemost. 2012 Jan 18. [Epub ahead of print]
  53. Bershad EM, Suarez JI. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. Neurocrit Care. 2010;12(3):403-413. (Review)
  54. Bechtel BF, Nunez TC, Lyon JA, et al. Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature review. Int J Emerg Med. 2011;4(1):40. (Review, practice guidelines)
  55. Safaoui MN, Aazami R, Hotz H, et al. A promising new alternative for the rapid reversal of warfarin coagulopathy in traumatic intracranial hemorrhage. Am J Surg. 2009;197(6):785-790. (Retrospective; 28 patients)
  56. Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49(6):1171-1177. (Prospective case-control; 82 patients)
  57. * Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;181(9):492-497. (Review, practice guidelines)
  58. Yasaka M, Oomura M, Ikeno K, et al. Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. Ann Hematol. 2003;82(2):121-123. (Case report)
  59. Ostermann H, Haertel S, Knaub S, et al. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98(4):790-797. (Prospective observational; 15 patients)
  60. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol. 2001;115(4):998-1001. (Prospective observational; 10 patients)
  61. Butler AC, Tait RC. Management of oral anticoagulant-induced intracranial haemorrhage. Blood Rev. 1998;12(1):35-44. (Review)
  62. van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118(3):313-320. (Prospective open-label randomized controlled trial; 93 patients)
  63. Cartmill M, Dolan G, Byrne JL, et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg. 2000;14(5):458-461. (Prospective cohort; 6 patients)
  64. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992;23(7):972-977. (Retrospective case-control; 17 patients)
  65. * Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37(6):1465-1470. (Retrospective; 55 patients)
  66. Guest JF, Watson HG, Limaye S. Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United kingdom. Clin Ther. 2010;32(14):2478-2493. (Cost analysis)
  67. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost. 2006;32(1):77-85. (Review)
  68. Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol. 2003;1(2):112-119. (Review)
  69. Hoffman M, Monroe DM 3rd. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol. 2001;38(4 Suppl 12):6-9. (Review)
  70. Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy. 2006;26(8):1091-1098. (Prospective observational; 16 patients)
  71. Sorensen B, Johansen P, Nielsen GL, et al. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis. 2003;14(5):469-477. (Prospective; 7 patients)
  72. Stein DM, Dutton RP, Kramer ME, et al. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. J Trauma. 2009;66(1):63-75. (Retrospective; 179 patients)
  73. Brown CV, Foulkrod KH, Lopez D, et al. Recombinant factor VIIa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients. J Trauma. 2010;68(2):348-352. (Retrospective; 28 patients)
  74. Park P, Fewel ME, Garton HJ, et al. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery. 2003;53(1):34-39. (Retrospective; 9 patients)
  75. Bartal C, Freedman J, Bowman K, et al. Coagulopathic patients with traumatic intracranial bleeding: defining the role of recombinant factor VIIa. J Trauma. 2007;63(4):725-732. (Prospective case series; 15 patients)
  76. Roitberg B, Emechebe-Kennedy O, Amin-Hanjani S, et al. Human recombinant factor VII for emergency reversal of coagulopathy in neurosurgical patients: a retrospective comparative study. Neurosurgery. 2005;57(5):832-836. (Retrospective controlled; 53 patients)
  77. Brody DL, Aiyagari V, Shackleford AM, et al. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care. 2005;2(3):263-267. (Retrospective; 27 patients)
  78. Nishijima DK, Dager WE, Schrot RJ, et al. The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage. Acad Emerg Med. 2010;17(3):244-251. (Retrospective case-control, 40 patients)
  79. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc. 2004;79(12):1495-1500. (Retrospective; 7 patients)
  80. Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol. 2004;41(1 Suppl 1):65-69. (Review)
  81. Mohr AM, Holcomb JB, Dutton RP, et al. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma. Crit Care. 2005;9 Suppl 5:S37-42. (Review)
  82. Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol. 2004;41(1 Suppl 1):20-24. (Review)
  83. Stein DM, Dutton RP, Kramer ME, et al. Recombinant factor VIIa: decreasing time to intervention in coagulopathic patients with severe traumatic brain injury. J Trauma. 2008;64(3):620-628. (Retrospective; 63 patients)
  84. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999;95(4 Suppl 1):S13-17. (Review)
  85. Lusher JM. Prediction and management of adverse events associated with the use of factor IX complex concentrates. Semin Hematol. 1993;30(2 Suppl 1):36-40. (Review)
  86. Thomas GO, Dutton RP, Hemlock B, et al. Thromboembolic complications associated with factor VIIa administration. J Trauma. 2007;62(3):564-569. (Retrospective; 285 patients)
  87. O’Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295(3):293-298. (Retrospective; 431 patients)
  88. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20):2127-2137. (Prospective, randomized controlled trial; 841 patients)
  89. Yuan ZH, Jiang JK, Huang WD, et al. A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia. J Clin Neurosci. 2010;17(6):685-693. (Meta-analysis; 5 studies)
  90. Levy JH, Fingerhut A, Brott T, et al. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion. 2006;46(6):919-933. (Meta-analysis; 13 studies)
  91. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33(4):883-890. (Systematic review; 483 articles)
  92. Phan TG, Koh M, Wijdicks EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol. 2000;57(12):1710-1713. (Retrospective; 141 patients)
  93. Roquer J, Rodriguez Campello A, Gomis M, et al. Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. J Neurol. 2005;252(4):412-416. (Prospective observational; 194 patients)
  94. Saloheimo P, Ahonen M, Juvela S, et al. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006;37(1):129-133. (Retrospective; 208 patients)
  95. Lacut K, van der Maaten J, Le Gal G, et al. Antiplatelet drugs and risk of venous thromboembolism: results from the EDITH case-control study. Haematologica. 2008;93(7):1117-1118. (Prospective case-control; 402 patients)
  96. Naidech AM, Jovanovic B, Liebling S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009;40(7):2398-2401. (Prospective observational; 68 patients)
  97. Toyoda K, Okada Y, Minematsu K, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology. 2005;65(7):1000-1004. (Retrospective; 57 patients)
  98. Caso V, Paciaroni M, Venti M, et al. Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. Cerebrovasc Dis. 2007;24(2-3):215-218. (Prospective observational; 457 patients)
  99. Sansing LH, Messe SR, Cucchiara BL, et al. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology. 2009;72(16):1397-1402. (Prospective observational; 282 patients)
  100. Foerch C, Sitzer M, Steinmetz H, et al. Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke. 2006;37(8):2165-2167. (Prospective observational; 1691 patients)
  101. Reymond MA, Marbet G, Radu EW, et al. Aspirin as a risk factor for hemorrhage in patients with head injuries. Neurosurg Rev. 1992;15(1):21-25. (Retrospective review; 198 patients)
  102. Ohm C, Mina A, Howells G, et al. Effects of antiplatelet agents on outcomes for elderly patients with traumatic intracranial hemorrhage. J Trauma. 2005;58(3):518-522. (Retrospective observational; 179 patients)
  103. Rozzelle CJ, Wofford JL, Branch CL. Predictors of hospital mortality in older patients with subdural hematoma. J Am Geriatr Soc. 1995;43(3):240-244. (Retrospective observational; 157 patients)
  104. Spektor S, Agus S, Merkin V, et al. Low-dose aspirin prophylaxis and risk of intracranial hemorrhage in patients older than 60 years of age with mild or moderate head injury: a prospective study. J Neurosurg. 2003;99(4):661-665. (Prospective observational; 231 patients)
  105. Fortuna GR, Mueller EW, James LE, et al. The impact of preinjury antiplatelet and anticoagulant pharmacotherapy on outcomes in elderly patients with hemorrhagic brain injury. Surgery. 2008;144(4):598-605. (Retrospective; 416 patients)
  106. Ahmed N, Bialowas C, Kuo YH, et al. Impact of preinjury anticoagulation in patients with traumatic brain injury. South Med J. 2009;102(5):476-480. (Retrospective review; 92 patients)
  107. Downey DM, Monson B, Butler KL, et al. Does platelet administration affect mortality in elderly head-injured patients taking antiplatelet medications? Am Surg. 2009;75(11):1100-1103. (Retrospective review; 328 patients)
  108. Naidech AM, Bassin SL, Bernstein RA, et al. Reduced platelet activity is more common than reported anti-platelet medication use in patients with intracerebral hemorrhage. Neurocrit Care. 2009;11(3):307-310. (Prospective observational; 72 patients)
  109. Campbell PG, Sen A, Yadla S, et al. Emergency reversal of antiplatelet agents in patients presenting with an intracranial hemorrhage: a clinical review. World Neurosurg. 2010;74(2-3):279-285. (Meta-analysis; 20 trials)
  110. Bonville DJ, Ata A, Jahraus CB, et al. Impact of preinjury warfarin and antiplatelet agents on outcomes of trauma patients. Surgery. 2011;150(4):861-868. (Retrospective study; 3436 patients)
  111. Washington CW, Schuerer DJ, Grubb RL, et al. Platelet transfusion: an unnecessary risk for mild traumatic brain injury patients on antiplatelet therapy. J Trauma. 2011;71(2):358-363. (Retrospective; in 1101 patients of whom 113 received antiplatelet therapy)
  112. Ducruet AF, Hickman ZL, Zacharia BE, et al. Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage. Neurol Res. 2010;32(7):706-710. (Retrospective; 66 patients)
  113. Creutzfeldt CJ, Weinstein JR, Longstreth WT, et al. Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2009;18(3):221-228. (Retrospective; 368 patients)
  114. Broderick JP. Evidence against rapid reversal of antiplatelet medications in acute intracerebral hemorrhage. Neurology. 2009;72(16):1376-1377. (Editorial)
  115. Bachelani AM, Bautz JT, Sperry JL, et al. Assessment of platelet transfusion for reversal of aspirin after traumatic brain injury. Surgery. 2011;150(4):836-843. (Retrospective observational; 84 patients).
  116. Norfolk DR, Ancliffe PJ, Contreras M, et al. Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27-28 November 1997. Synopsis of background papers. Br J Haematol. 1998;101(4):609-617. (Consensus statement/review/practice guidelines)
  117. de Gans K, de Haan RJ, Majoie CB, et al. PATCH: platelet transfusion in cerebral haemorrhage: study protocol for a multicentre, randomised, controlled trial. BMC Neurol. 2010;10:19. (Description of planned randomized controlled trial)
  118. Hillbom ME, Huhtakangas JT. Platelet transfusion in acute intracerebral hemorrhage. Clinicaltrials.gov number nct00699621.2008.http://www.clinicaltrials.gov/ct2/show/NCT00699621. Accessed on Oct. 23, 2011. (Description of randomized controlled trial currently enrolling)
  119. Flordal PA, Sahlin S. Use of desmopressin to prevent bleeding complications in patients treated with aspirin. Br J Surg. 1993;80(6):723-724. (Retrospective review; 11 patients)
  120. Reiter RA, Mayr F, Blazicek H, et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood. 2003;102(13):4594-4599. (Prospective trial; 20 subjects)
  121. Leithauser B, Zielske D, Seyfert UT, et al. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc. 2008;39(1-4):293-302. (Prospective randomized trial; 17 subjects)
  122. Altman R, Scazziota A, DE Lourdes Herrera M, et al. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost. 2006;4(9):2022-2027. (Prospective trial)
  123. Monroe DM, Hoffman M, Allen GA, et al. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost. 2000;26(4):373-377. (Review)
  124. Holst J, Lindblad B, Bergqvist D, et al. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers. Blood Coagul Fibrinolysis. 1994;5(5):795-803. (Prospective trial; 50 subjects)
  125. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106(20):2550-2554. (Randomized controlled trial; 16 subjects)
  126. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329. (Multicenter randomized controlled trial; 821 patients)
  127. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587. (Multicenter randomized controlled trial; 624 patients)
  128. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372(9646):1303-1309. (Observational study comparing 664 patients treated at 3-4.5 hours to 11,865 patients treated in < 3 hours)
  129. Goldstein JN, Marrero M, Masrur S, et al. Management of thrombolysis-associated symptomatic intracerebral hemorrhage. Arch Neurol. 2010;67(8):965-969. (Retrospective review; 20 patients)
  130. Piriyawat P, Morgenstern LB, Yawn DH, et al. Treatment of acute intracerebral hemorrhage with epsilon-aminocaproic acid: a pilot study. Neurocrit Care. 2004;1(1):47-51. (Prospective observational; 14 patients)
  131. Marder VJ. Thrombolytic therapy. In: Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. 2nd ed. Philadelphia, PA: Elsevier; 2007:491-501. (Textbook)
  132. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Circulation. 2007;116(16):e391-413. (Review and clinical guidelines)
  133. * Morgenstern LB, Hemphill JC 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41(9):2108-2129. (Review and clinical guidelines)
  134. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126-2130. (Prospective observational cohort study; 2229 stents)
  135. Bhala N, Taggar JS, Rajasekhar P, et al. Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment. BMJ. 2011;343:d4264. (Clinical review)
  136. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352. (Randomized controlled trial; 2539 patients)
  137. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. (Randomized controlled trial; 18,113 patients)
  138. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303. (Prospective single arm dose-finding trial; 80 subjects)
  139. Watanabe M, Siddiqui FM, Qureshi AI. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocrit Care. 2012;16(1):203-209. (Review)
  140. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-1127. (Review)
  141. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573-1579. (Randomized crossover trial; 12 subjects)
  142. Wienen W. Effect of recombinant factor VIIa or activated prothrombin complex concentrate on the bleeding time in anesthetized rats during anticoagulant treatment with the direct thrombin inhibitor dabigatran. J Thromb Haemost. 2008;3(Suppl. 1):1703. (Animal study)
  143. Ovanesov MV, Panteleev MA, Sinauridze EI, et al. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution. Blood Coagul Fibrinolysis. 2008;19(8):743-755. (Review)
  144. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesth. 2002;49(6):S11-25. (Review)
  145. Ibbotson SH, Grant PJ, Kerry R, et al. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro. Thromb Haemost. 1991;65(1):64-66. (Prospective trial; 10 subjects)
  146. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. (Randomized controlled trial; 14,264 subjects)
  147. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. (Randomized controlled trial; 3449 subjects)
  148. Cao YB, Zhang JD, Shen H, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2010;66(11):1099-1108. (Meta-analysis; 8 randomized controlled trials)
  149. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263-1271. (Ex-vivo laboratory study)
  150. Guidelines for the management of severe traumatic brain injury. J Neurotrauma. 2007;24 Suppl 1:S1-106. (Review and clinical guidelines)
  151. Bederson JB, Connolly ES Jr., Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009;40(3):994-1025. (Review and clinical guidelines)
  152. Diringer MN, Bleck TP, Claude Hemphill J 3rd, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211-240. (Review and clinical guidelines)   
Get A Sample Issue Of Emergency Medicine Practice
Enter your email to get your copy today! Plus receive updates on EB Medicine every month.
Please provide a valid email address.